C2N Diagnostics Revenue
Biotechnology Research • 
St Louis, Missouri, United States • 101-200 Employees
C2N Diagnostics revenue & valuation
| Annual revenue | $7,500,000 |
| Revenue per employee | $69,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $24,000,000 |
| Total funding | $63,500,000 |
Key Contacts at C2N Diagnostics
Brian Farrell
Director, Head Of Us Sales
Joel Braunstein
Ceo, Co-Founder And Board Member
Carrie Dammon
Director Of Product Management, Marketed Products
Tammy Liebling-Venus
Director Of Revenue Cycle Management
Elizabeth Wahl
Director Of Product Management, New Products
Joni Henderson
Senior Director, Corporate Communications And Strategic Growth
V. Venkatesh
Senior Director Project Management
Amy Brock
Marketing Director
Brianne Peters
Senior Director Commercial Operations
Janet Bonner
Director Of Market Access
Company overview
| Headquarters | 20 S Sarah St, St Louis, Missouri 63108, US |
| Phone number | +12263424 |
| Websites | |
| NAICS | 541714 |
| SIC | 873 |
| Founded | 2007 |
| Employees | 101-200 |
| Socials |
C2N Diagnostics Email Formats
C2N Diagnostics uses 2 email formats. The most common is {first initial}{last name} (e.g., jdoe@c2ndiagnostics.com), used 69.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@c2ndiagnostics.com | 69.2% |
{last name}{last name} | doedoe@c2ndiagnostics.com | 30.8% |
About C2N Diagnostics
C₂N Diagnostics’ vision is to bring Clarity Through Innovation™. It focuses its therapeutic discovery efforts around mechanism-based approaches to prevent or stop the progression of human neurological disorders. Diagnostic efforts revolve around bringing accurate, widely accessible, and cost-effective blood tests to the clinic for the betterment of patient care and brain health monitoring. Its lead commercial product, the PrecivityAD™ blood test, is a mass spectrometry-based test performed in C₂N’s CLIA-certified lab that measures in blood multiple analytes including Aβ42, Aβ40, and apolipoprotein E isoforms. While the test by itself cannot diagnose Alzheimer’s disease — which is a clinical diagnosis made by a health care provider — the test is an important new tool for physicians to aid in the evaluation process. PrecivityAD™, which can only be ordered through a health care provider, predicts brain amyloid plaques as determined by PET scan results and in 2019 it received a Breakthrough Device Designation from the U.S. Food and Drug Administration. The PrecivityAD™ blood test also has achieved the CE Mark from the European Union. For more information visit www.C2N.com.
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
C2N Diagnostics has 62 employees across 12 departments.
Departments
Number of employees
Funding Data
Explore C2N Diagnostics's funding history, including investment rounds, total capital raised, and key backers.
C2N Diagnostics Tech Stack
Discover the technologies and tools that power C2N Diagnostics's digital infrastructure, from frameworks to analytics platforms.
Font scripts
JavaScript libraries
JavaScript libraries
Hosting
Ecommerce
Development
Security
JavaScript frameworks
Security
Miscellaneous
JavaScript libraries
Shipping carriers
Sweden
Spain
Italy
Philippines
Israel
SingaporeFrequently asked questions
4.8
40,000 users
